CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses

Xun Sun, Hisakata Yamada, Kensuke Shibata, Hiromi Muta, Kenzaburo Tani, Eckhard R. Podack, Yoichiro Iwakura, Yasunobu Yoshikai

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We have previously found that CD30 ligand (CD30L; CD153)/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation, at least partly via downregulation of IL-2 production. In this study, we investigated the role of CD30L in the development of colitis experimentally induced by dextran sulfate sodium (DSS), in which IL-17A is involved in the pathogenesis. CD30L-/- mice were resistant to both acute colitis induced by administration of 3 to ∼5% DSS and to chronic colitis induced by administration of 1.5% DSS on days 0-5, 10-15, and 20-25 as assessed by weight loss, survival rate, and histopathology. The levels of IFN-γ, IL-17A, and IL-10 were significantly lower but the IL-2 level higher in the lamina propria T lymphocytes of CD30L-/- mice than those in lamina propria T lymphocytes of wild-type mice after DSS administration. Soluble murine CD30-Ig fusion protein, which was capable of inhibiting Th17 cell differentiation in vitro, ameliorated both types of DSS-induced colitis in wild-type mice. Modulation of CD30L/CD30 signaling by soluble CD30 could be a novel biological therapy for inflammatory diseases associated with Th17 responses.

Original languageEnglish
Pages (from-to)7671-7680
Number of pages10
JournalJournal of Immunology
Volume185
Issue number12
DOIs
StatePublished - Dec 15 2010
Externally publishedYes

Fingerprint

CD30 Ligand
Dextran Sulfate
Biological Therapy
Colitis
Th17 Cells
Interleukin-17
T-Lymphocytes
Interleukin-2
Cell Differentiation
Mucous Membrane
Cell Communication
Interleukin-10
Weight Loss
Down-Regulation

ASJC Scopus subject areas

  • Immunology

Cite this

Sun, X., Yamada, H., Shibata, K., Muta, H., Tani, K., Podack, E. R., ... Yoshikai, Y. (2010). CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. Journal of Immunology, 185(12), 7671-7680. https://doi.org/10.4049/jimmunol.1002229

CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. / Sun, Xun; Yamada, Hisakata; Shibata, Kensuke; Muta, Hiromi; Tani, Kenzaburo; Podack, Eckhard R.; Iwakura, Yoichiro; Yoshikai, Yasunobu.

In: Journal of Immunology, Vol. 185, No. 12, 15.12.2010, p. 7671-7680.

Research output: Contribution to journalArticle

Sun, X, Yamada, H, Shibata, K, Muta, H, Tani, K, Podack, ER, Iwakura, Y & Yoshikai, Y 2010, 'CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses', Journal of Immunology, vol. 185, no. 12, pp. 7671-7680. https://doi.org/10.4049/jimmunol.1002229
Sun, Xun ; Yamada, Hisakata ; Shibata, Kensuke ; Muta, Hiromi ; Tani, Kenzaburo ; Podack, Eckhard R. ; Iwakura, Yoichiro ; Yoshikai, Yasunobu. / CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses. In: Journal of Immunology. 2010 ; Vol. 185, No. 12. pp. 7671-7680.
@article{e6f4888d82e44c4783c98b245f180a87,
title = "CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses",
abstract = "We have previously found that CD30 ligand (CD30L; CD153)/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation, at least partly via downregulation of IL-2 production. In this study, we investigated the role of CD30L in the development of colitis experimentally induced by dextran sulfate sodium (DSS), in which IL-17A is involved in the pathogenesis. CD30L-/- mice were resistant to both acute colitis induced by administration of 3 to ∼5{\%} DSS and to chronic colitis induced by administration of 1.5{\%} DSS on days 0-5, 10-15, and 20-25 as assessed by weight loss, survival rate, and histopathology. The levels of IFN-γ, IL-17A, and IL-10 were significantly lower but the IL-2 level higher in the lamina propria T lymphocytes of CD30L-/- mice than those in lamina propria T lymphocytes of wild-type mice after DSS administration. Soluble murine CD30-Ig fusion protein, which was capable of inhibiting Th17 cell differentiation in vitro, ameliorated both types of DSS-induced colitis in wild-type mice. Modulation of CD30L/CD30 signaling by soluble CD30 could be a novel biological therapy for inflammatory diseases associated with Th17 responses.",
author = "Xun Sun and Hisakata Yamada and Kensuke Shibata and Hiromi Muta and Kenzaburo Tani and Podack, {Eckhard R.} and Yoichiro Iwakura and Yasunobu Yoshikai",
year = "2010",
month = "12",
day = "15",
doi = "10.4049/jimmunol.1002229",
language = "English",
volume = "185",
pages = "7671--7680",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses

AU - Sun, Xun

AU - Yamada, Hisakata

AU - Shibata, Kensuke

AU - Muta, Hiromi

AU - Tani, Kenzaburo

AU - Podack, Eckhard R.

AU - Iwakura, Yoichiro

AU - Yoshikai, Yasunobu

PY - 2010/12/15

Y1 - 2010/12/15

N2 - We have previously found that CD30 ligand (CD30L; CD153)/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation, at least partly via downregulation of IL-2 production. In this study, we investigated the role of CD30L in the development of colitis experimentally induced by dextran sulfate sodium (DSS), in which IL-17A is involved in the pathogenesis. CD30L-/- mice were resistant to both acute colitis induced by administration of 3 to ∼5% DSS and to chronic colitis induced by administration of 1.5% DSS on days 0-5, 10-15, and 20-25 as assessed by weight loss, survival rate, and histopathology. The levels of IFN-γ, IL-17A, and IL-10 were significantly lower but the IL-2 level higher in the lamina propria T lymphocytes of CD30L-/- mice than those in lamina propria T lymphocytes of wild-type mice after DSS administration. Soluble murine CD30-Ig fusion protein, which was capable of inhibiting Th17 cell differentiation in vitro, ameliorated both types of DSS-induced colitis in wild-type mice. Modulation of CD30L/CD30 signaling by soluble CD30 could be a novel biological therapy for inflammatory diseases associated with Th17 responses.

AB - We have previously found that CD30 ligand (CD30L; CD153)/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation, at least partly via downregulation of IL-2 production. In this study, we investigated the role of CD30L in the development of colitis experimentally induced by dextran sulfate sodium (DSS), in which IL-17A is involved in the pathogenesis. CD30L-/- mice were resistant to both acute colitis induced by administration of 3 to ∼5% DSS and to chronic colitis induced by administration of 1.5% DSS on days 0-5, 10-15, and 20-25 as assessed by weight loss, survival rate, and histopathology. The levels of IFN-γ, IL-17A, and IL-10 were significantly lower but the IL-2 level higher in the lamina propria T lymphocytes of CD30L-/- mice than those in lamina propria T lymphocytes of wild-type mice after DSS administration. Soluble murine CD30-Ig fusion protein, which was capable of inhibiting Th17 cell differentiation in vitro, ameliorated both types of DSS-induced colitis in wild-type mice. Modulation of CD30L/CD30 signaling by soluble CD30 could be a novel biological therapy for inflammatory diseases associated with Th17 responses.

UR - http://www.scopus.com/inward/record.url?scp=78650652886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650652886&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1002229

DO - 10.4049/jimmunol.1002229

M3 - Article

C2 - 21068411

AN - SCOPUS:78650652886

VL - 185

SP - 7671

EP - 7680

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -